Cybin Inc. provided an update on its neuropsychiatry platform and highlighted significant clinical and regulatory milestones. The company successfully completed enrollment of 36 participants in its Phase 2 study of CYB004, its deuterated dimethyltryptamine program for Generalized Anxiety Disorder (GAD), with topline data expected in Q1 2026.
Cybin continues to advance CYB003, its proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of Major Depressive Disorder (MDD). Dosing is ongoing in the first pivotal study, APPROACH, which expects to enroll 220 patients across 45 U.S. clinical sites.
The company emphasized its sector-leading intellectual property portfolio, which now includes over 100 granted patents and more than 250 pending applications, positioning Cybin as a leader in Phase 3 psychedelic therapeutics. Cybin also noted market validation through AbbVie's acquisition of Gilgamesh Pharmaceuticals’ bretisilocin program, supporting the thesis that IP and novel drug development platforms are fundamental value drivers in the neuropsychiatry space.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.